Pharma Execs Say Senate Drug Pricing Bill Targets Industry, Not The Problem
Industry CEOs expressed reservations about the US drug pricing legislation in the Senate, but said they support reforms that will impact patient affordability, during Q2 calls.
You may also be interested in...
While it works on merging with Allergan, AbbVie is tracking biosimilar sales erosion to Humira, the promising launch of Skyrizi and the growth of Imbruvica and Venclexta. It is terminating a Phase II study of a tau-targeting antibody and worried about aspects of the Senate drug pricing bill.
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.